Low-dose anti-HIV drug efavirenz mitigates retinal vascular lesions in a mouse model of Alzheimer’s disease

A small dose of the anti-HIV drug efavirenz (EFV) was previously discovered to activate CYP46A1, a cholesterol-eliminating enzyme in the brain, and mitigate some of the manifestation of Alzheimer’s disease in 5XFAD mice(a mouse model foe Alzheimers disease. Herein, we investigated the retina of these animals, which were found to have genetically determined retinal vascular lesions associated with deposits within the retinal pigment epithelium and sub retinal space.. Thus gain an unbiased insight into the processes in the retina that could be to affected by efavirenz treatment, the proteomic approach was used to compare the retinas of efavirenz -treated and control 5XFAD mice.